JP2002521065A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002521065A5 JP2002521065A5 JP2000562554A JP2000562554A JP2002521065A5 JP 2002521065 A5 JP2002521065 A5 JP 2002521065A5 JP 2000562554 A JP2000562554 A JP 2000562554A JP 2000562554 A JP2000562554 A JP 2000562554A JP 2002521065 A5 JP2002521065 A5 JP 2002521065A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- amino acid
- acid residue
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 description 25
- 125000000539 amino acid group Chemical group 0.000 description 24
- 230000035772 mutation Effects 0.000 description 22
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 15
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 208000004731 long QT syndrome Diseases 0.000 description 7
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 6
- 235000004279 alanine Nutrition 0.000 description 6
- 235000003704 aspartic acid Nutrition 0.000 description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 239000004474 valine Substances 0.000 description 6
- 230000007774 longterm Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000007654 immersion Methods 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
Images
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12284798A | 1998-07-27 | 1998-07-27 | |
| US09/122,847 | 1998-07-27 | ||
| US09/226,012 US6207383B1 (en) | 1998-07-27 | 1999-01-06 | Mutations in and genomic structure of HERG—a long QT syndrome gene |
| US09/226,012 | 1999-01-06 | ||
| PCT/US1999/016337 WO2000006772A1 (en) | 1998-07-27 | 1999-07-20 | Mutations in and genomic structure of herg - a long qt syndrome gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002521065A JP2002521065A (ja) | 2002-07-16 |
| JP2002521065A5 true JP2002521065A5 (enExample) | 2006-09-14 |
Family
ID=26820952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000562554A Withdrawn JP2002521065A (ja) | 1998-07-27 | 1999-07-20 | Ｈｅｒｇ−長期ｑｔ症候群遺伝子中の突然変異およびそのゲノム構造 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US6207383B1 (enExample) |
| EP (2) | EP1102863A4 (enExample) |
| JP (1) | JP2002521065A (enExample) |
| AU (2) | AU774194B2 (enExample) |
| CA (1) | CA2336236C (enExample) |
| WO (1) | WO2000006772A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274332B1 (en) * | 1995-12-22 | 2001-08-14 | Univ. Of Utah Research Foundation | Mutations in the KCNE1 gene encoding human minK which cause arrhythmia susceptibility thereby establishing KCNE1 as an LQT gene |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
| US6852704B1 (en) * | 1999-01-19 | 2005-02-08 | The Children's Hospital Of Philadelphia | Reverse gene therapy |
| US7282489B2 (en) * | 2000-01-19 | 2007-10-16 | The Children's Hospital Of Philadelphia | Compositions and methods for performing reverse gene therapy |
| US7179597B2 (en) | 2000-04-13 | 2007-02-20 | Georgetown University | Genetic diagnosis for QT prolongation related adverse drug reactions |
| DE10224534A1 (de) * | 2002-05-31 | 2003-12-11 | Juergen Dolderer | Verfahren zum Diagnostizieren des colorektaien Karzinoms in einer Gewebeprobe und Mittel zur Behandlung |
| KR20040023166A (ko) * | 2002-09-11 | 2004-03-18 | 학교법인 계명기독학원 | 유전자 돌연변이 및 ｓｎｐ 탐지용 프라이머를 이용한ｑｔ연장증후군의 진단방법 |
| US7537928B2 (en) * | 2003-08-22 | 2009-05-26 | Masonic Medical Research Laboratory | Mutations in ion channel proteins associated with sudden cardiac death |
| CN1845726A (zh) | 2003-09-04 | 2006-10-11 | 波塞东医药公司 | 用于治疗心脏心律失常的erg通道开放剂 |
| US20050064547A1 (en) * | 2003-09-24 | 2005-03-24 | Brown Arthur M. | Vectors and transfected cells |
| WO2005042732A2 (en) * | 2003-10-28 | 2005-05-12 | Wisconsin Alumni Research Foundation | STABLE CELL LINES EXPRESSING HERG1a AND HERG1b |
| US20070239230A1 (en) * | 2004-12-17 | 2007-10-11 | Medtronic, Inc. | System and method for regulating cardiac triggered therapy to the brain |
| US7833718B2 (en) * | 2006-11-06 | 2010-11-16 | Masonic Medical Research Laboratory | CACNA1C nucleic acid mutations as indicators of shorter than normal QT interval and ST segment elevation associated with sudden cardiac death |
| US20090047703A1 (en) * | 2007-08-17 | 2009-02-19 | University Of Maryland, Baltimore | ERG-1 Peptides and Polynucleotides and Their Use in the Treatment and Diagnosis of Disease |
| WO2009140724A1 (en) * | 2008-05-20 | 2009-11-26 | Victor Chang Cardiac Research Institute Limited | Herg mutants and uses thereof |
| WO2017173257A1 (en) * | 2016-04-01 | 2017-10-05 | The Rockefeller University | ASSAY FOR hERG CHANNEL SENSITIVITY TO SMALL MOLECULE PHARMACOLOGICAL AGENTS |
| EP3512938B1 (en) * | 2016-09-15 | 2024-08-28 | The Governors Of The University Of Alberta | Recombinant cardiomyocytes and cardiomyocyte cell lines expressing herg |
| CN119390821A (zh) * | 2017-08-15 | 2025-02-07 | 伊兰科美国公司 | 兽药用IgG Fc变体 |
| CN117487907B (zh) * | 2023-12-29 | 2024-04-23 | 湖南家辉生物技术有限公司 | Kcnh2基因突变体、突变体蛋白、试剂、试剂盒及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599673A (en) | 1995-03-09 | 1997-02-04 | University Of Utah Research Foundation | Long QT syndrome genes |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
-
1999
- 1999-01-06 US US09/226,012 patent/US6207383B1/en not_active Expired - Lifetime
- 1999-07-20 JP JP2000562554A patent/JP2002521065A/ja not_active Withdrawn
- 1999-07-20 CA CA2336236A patent/CA2336236C/en not_active Expired - Fee Related
- 1999-07-20 EP EP99935710A patent/EP1102863A4/en not_active Withdrawn
- 1999-07-20 EP EP04008958A patent/EP1553190A3/en not_active Withdrawn
- 1999-07-20 WO PCT/US1999/016337 patent/WO2000006772A1/en not_active Ceased
- 1999-07-20 AU AU51133/99A patent/AU774194B2/en not_active Ceased
-
2000
- 2000-12-14 US US09/735,995 patent/US20010034024A1/en not_active Abandoned
-
2003
- 2003-10-30 US US10/696,708 patent/US7297489B2/en not_active Expired - Fee Related
-
2004
- 2004-05-11 AU AU2004202006A patent/AU2004202006A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002521065A5 (enExample) | ||
| US9816129B2 (en) | Bioprobes and methods of use thereof | |
| CA2336236A1 (en) | Mutations in and genomic structure of herg - a long qt syndrome gene | |
| JP2010075182A5 (enExample) | ||
| CA2735129A1 (en) | Syngap1 dysfunctions and uses thereof in diagnostic and therapeutic applications for mental retardation | |
| AU2008222563A1 (en) | Assessment of risk for colorectal cancer | |
| KR101748679B1 (ko) | 섬유증 감수성 유전자 및 이의 용도 | |
| CA2362527A1 (en) | A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer | |
| JP2003530814A5 (enExample) | ||
| US20050170500A1 (en) | Methods for identifying risk of melanoma and treatments thereof | |
| CA2416545A1 (en) | Common polymorphism in scn5a implicated in drug-induced cardiac arrhythmia | |
| US20080199480A1 (en) | Methods for Identifying Risk of Type II Diabetes and Treatments Thereof | |
| WO2007140599A1 (en) | Assessment of risk for colorectal cancer | |
| JP6465655B2 (ja) | 発作障害及び運動障害に関連する遺伝子及びその変異 | |
| US6682888B1 (en) | Genes expressed in alzheimer's disease | |
| EP2573169B1 (en) | Cartilage-specific hif-2 transgenic mouse as an animal model for arthritis, and use thereof | |
| JP2002521045A5 (enExample) | ||
| CA2368802A1 (en) | Mutations associated with iron disorders | |
| CA2158791A1 (en) | Dna sequences encoding the machado-joseph disease gene and uses thereof | |
| WO2000042196B1 (en) | Human methionine synthase reductase: cloning, and methods for evaluating risk of neural tube defects, cardiovascular disease, cancer, and down's syndrome | |
| JP2004531241A5 (enExample) | ||
| JP3998934B2 (ja) | 電子伝達フラビン蛋白脱水素酵素遺伝子とそれを利用するグルタル酸尿症ｉｉ型の診断方法 | |
| JP4034818B1 (ja) | 遺伝子検出用担体、及びインターフェロン療法の有効性を検出するためのその使用 | |
| JP4040834B2 (ja) | ２本鎖ｄｎａの分析方法 | |
| JP2010130931A (ja) | ヘリコバクター属の微生物由来の核酸を特異的に増幅するためのプライマーセット、前記微生物を検知および／または分類するための方法 |